Back to today’s briefing

Story perspectives

India Reviews Ranitidine Amid Cancer Risk Concerns

7/28/2025

24 3

Summary

Story summary

The Indian government is taking a closer look at Ranitidine medications like Rantac and Zinetac amid rising cancer risk fears tied to N-Nitrosodimethylamine (NDMA). The Central Drugs Standard Control Organization is evaluating NDMA levels and storage methods. Although no ban exists, doctors are recommending safer alternatives, urging patients to seek professional advice before altering their treatments.

1 of 1

Story summary

The Indian government is taking a closer look at Ranitidine medications like Rantac and Zinetac amid rising cancer risk fears tied to N-Nitrosodimethylamine (NDMA). The Central Drugs Standard Control Organization is evaluating NDMA levels and storage methods. Although no ban exists, doctors are recommending safer alternatives, urging patients to seek professional advice before altering their treatments.